Tag: Secondary Hyperparathyroidism
Amgen’s Parsabiv gets EC approval for treating SHPT
American biopharma company Amgen’s Parsabiv drug has been approved by the European Commission for treating secondary hyperparathyroidism. Secondary Hyperparathyroidism (sHPT) is a serious and chronic ... Read More